Dianthus Therapeutics, Inc.
DNTH
Rang in aandelen
#3836
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Aandeelprijs
$77.80
Marktkapitalisatie
$4.35B
Verandering (1 dag)
-1.21%
Verandering (1 jaar)
122.10%
Land
US
Handel Dianthus Therapeutics, Inc. (DNTH)
Categorie
Healthcare
Koersgeschiedenis voor Dianthus Therapeutics, Inc. (DNTH)
Hoogste slotkoers: $80.75 op 2026-10-01
Laagste slotkoers: $225.69 op 2018-06-01
Laagste slotkoers: $225.69 op 2018-06-01
Koersgeschiedenis van Dianthus Therapeutics, Inc. van 2018 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 74.03% |
| 2025 | 79.27% |
| 2024 | 158.65% |
| 2023 | -30.65% |
| 2022 | -83.63% |
| 2021 | -32.46% |
| 2020 | -46.40% |
| 2019 | 100.40% |
| 2018 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
